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Abstract
Introduction: The purpose of this study was to evaluate the dosimetric and
radiobiological impact of intensity modulated proton therapy (IMPT) and
RapidArc planning for high-risk prostate cancer with seminal vesicles.
Methods: Ten high-risk prostate cancer cases were included in this
retrospective study. For each case, IMPT plans were generated using multiple
field optimisation (MFO) technique (two fields) with XiO treatment planning
system (TPS), whereas RapidArc plans were generated using double-arc
technique (two full arcs) with Eclipse TPS. IMPT and RapidArc plans were
optimised for a total prescription dose of 79.2 Gy (relative biological
effectiveness (RBE)) and 79.2 Gy, respectively, using identical dose–volume
constraints. IMPT and RapidArc plans were then normalised such that at least
95% of the planning target volume (PTV) received the prescription dose.
Results: The mean and maximum PTV doses were comparable in IMPT plans
(80.1  0.3 Gy (RBE) and 82.6  1.0 Gy (RBE) respectively) and RapidArc
plans (80.3  0.3 Gy and 82.8  0.6 Gy respectively) with P = 0.088 and
P = 0.499 respectively. The mean doses of the rectum and bladder were found
to be significantly lower in IMPT plans (16.9  5.8 Gy (RBE) and
17.5  5.4 Gy (RBE) respectively) when compared to RapidArc plans
(41.9  5.7 Gy and 32.5  7.8 Gy respectively) with P < 0.000 and P < 0.000
respectively. For the rectum, IMPT produced lower V30 (21.0  9.6% vs.
68.5  10.0%; P < 0.000), V50 (14.3  5.8% vs. 45.0  10.0%; P < 0.000) and
V70 (6.9  3.4% vs. 12.8  3.6%; P < 0.000) compared to RapidArc. For the
bladder, IMPT produced lower V30 (23.2  7.0% vs. 50.9  15.6%; P < 0.000)
and V50 (16.6  5.4% vs. 25.1  9.6%; P = 0.001), but similar V70
(9.7  3.5% vs. 10.5  4.2%; P = 0.111) compared to RapidArc. RapidArc
produced lower mean dose for both the right femoral head (19.5  4.2 Gy vs.
27.4  4.5 Gy (RBE); P < 0.000) and left femoral head (18.0  4.3 Gy vs.
28.0  5.6 Gy (RBE); P < 0.000). Both IMPT and RapidArc produced
comparable bladder normal tissue complication probability (NTCP)
(0.6  0.2% vs. 0.5  0.2%; P = 0.152). The rectal NTCP was found to be
lower using IMPT (0.8  0.7%) than using RapidArc (1.7  0.7%) with
P < 0.000. Conclusion: Both IMPT and RapidArc techniques provided
comparable mean and maximum PTV doses. For the rectum, IMPT produced
18 ª 2016 The Authors. Journal of Medical Radiation Sciences published by John Wiley & Sons Australia, Ltd on behalf of
Australian Institute of Radiography and New Zealand Institute of Medical Radiation Technology.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License,
which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and
no modifications or adaptations are made.
better dosimetric results in the low-, medium- and high-dose regions and
lower NTCP compared to RapidArc. For the bladder, the NTCP and
dosimetric results in the high-dose region were comparable in both sets of
plans, whereas IMPT produced better dosimetric results in the low- and
medium-dose regions.
Introduction
External beam radiation therapy (EBRT) continues to be
one of the most commonly used treatment techniques for
cancer treatment. RapidArc (a form of volumetric
modulated arc therapy (VMAT) implemented by Varian
Medical Systems, Palo Alto, CA) and intensity modulated
proton therapy (IMPT) are two most recent EBRT
modalities that are used to treat prostate cancer.1,2 One
of the fundamental differences between these two
techniques is that mega-voltage X-rays (photons) are used
for RapidArc delivery, whereas protons are used for
IMPT. Several researchers2–10 have investigated the
dosimetric impact of photon and proton therapy for the
prostate cancer. Earlier studies4–10 using proton therapy
were mostly focused on double scattering and uniform
scanning. One of the limitations of double scattering and
uniform scanning is the lack of a plan optimisation
feature. Specifically, in double scattering and uniform
scanning proton therapy (USPT), treatment planning is
based on the 3D conformal approach and utilises
apertures and range compensators. A more recent study5
on USPT planning for a high-risk prostate cancer showed
that USPT consistently produced better organ at risk
(OAR) results in the low- and medium-dose regions
when compared to RapidArc; however, in the high-dose
region, the dosimetric advantage of USPT over RapidArc
was not distinct when evaluated for all the cases
presented in the study.5
The literature comparing IMPT and VMAT for the
prostate cancer is very scarce. Vees et al.2 assessed various
treatment techniques including VMAT and IMPT for six
prostate cancer patients with sentinel nodes in the
pararectal region. The authors2 reported greater reduction
in OARs volume exposed to radiation using IMPT than
using VMAT. Georg et al.3 assessed the dosimetric
differences among VMAT, IMPT, carbon-ion therapy and
brachytherapy treatment of localised prostate cancer. The
comparison between IMPT and VMAT plans showed that
the IMPT produced better rectal and bladder results in
the low- and medium-dose regions, whereas the VMAT
produced better OAR (rectum and bladder) results in the
high-dose region.3 The OAR volume exposed to medium
and high doses could be potentially critical to reduce late
toxicities, especially for the rectum.11–13 Since the
literature comparing VMAT (or RapidArc) and IMPT for
a high-risk prostate cancer is very limited, further
investigation of these two evolving EBRT techniques is
needed. The main purpose of our study was to evaluate
the dosimetric and radiobiological impact of IMPT and
RapidArc for a high-risk prostate cancer with seminal
vesicles.
Materials and Methods
A total of 10 high-risk prostate cancer cases previously
treated with USPT at ProCure Proton Therapy Center,
Oklahoma City were selected for this retrospective study.
All 10 patients have consented to participation in the
Proton Collaborative Group (PCG) protocol REG001-09
(NCT01255748). Each case had undergone VisiCoil
fiducial markers (IBA, Schwarzenbruck, Sweden)
placement within the prostate. The computed tomography
(CT) simulation of each case was done on a General
Electric CT Scanner (General Electric Healthcare, Little
Chalfont, United Kingdom) in the feet-first supine
position using a Vac-Lok system (CIVCO Medical
Solutions, Kalona, Iowa) with slice thickness of 1.25 mm.
Per institutional protocol at ProCure Proton Therapy
Center, Oklahoma City, all patients were instructed to
drink a 16–32 oz of water in order to maintain a full
bladder 30–60 min prior to the CT simulation as well as
the beam delivery. For the rectum, either a rectal balloon
or 100 cc of saline was used based on the recommendation
from the attending physician.
The CT data set and contoured structures of each case
were reviewed in Velocity, version 2.8.0 (Varian Medical
Systems, Palo Alto, CA). The clinical target volume (CTV)
was defined as the prostate and seminal vesicles. The
planning target volume (PTV) was created by expanding
the CTV (i.e. 3 mm to the posterior and 4 mm elsewhere
to the CTV). The rectum, bladder, femoral heads and
other relevant structures for the prostate cancer treatment
were contoured per PCG protocol REG001-09 (NCT01
255748).
RapidArc plans were generated in the Eclipse treatment
planning system (TPS), version 11.01 (Varian Medical
Systems, Palo Alto, CA) using Varian Clinac iX 6 MV
beams. A total dose of 79.2 Gy was prescribed to the PTV
with 1.8 Gy per fraction. RapidArc plan of each case
consisted of 2 full arcs with their isocentre placed at the
centre of the PTV. Field sizes were selected based on the
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beam’s-eye-view graphics in the Eclipse TPS. RapidArc
plans were optimised using dose constraints provided in
Table 1. Dose calculations in RapidArc plans were
performed with the anisotropic analytical algorithm, and
the dose calculation grid size was set to 2.5 mm.
IMPT plan of each case was generated in the XiO TPS,
version 5.00 (CMS Inc., St. Louis, MO) using an IBA
proton machine (IBA, Louvain-la-Neuve, Belgium). For
each prostate case in this study, dose prescription to the
PTV was 79.2 (relative biological effectiveness (RBE))
with a fractional dose of 1.8 Gy (RBE). For the IMPT
planning, two parallel-opposed lateral fields were used to
target the PTV, and the isocentre of each proton field was
placed at the centre of the PTV (Fig. 1). For a given
proton field, a range uncertainty of 2.5% + 2 mm (i.e.
2.5% of water equivalent path length (skin edge to the
distal and proximal edges of the CTV) plus 2 mm) was
applied. During IMPT plan optimisation, both lateral
fields were combined together, and dose–volume
constraints (Table 1) in IMPT optimisation were selected
as the same ones as in the RapidArc plan optimisation.
Proton dose calculations were done using a pencil beam
algorithm,14 and the dose calculation grid size was set to
3 mm 9 3 mm 9 3 mm.
For plan evaluation purpose, both sets of plans
(RapidArc and IMPT) were normalised such that at least
95% of the PTV volume received the prescription dose.
For dose–volume histogram (DVH) analysis, the PTV was
evaluated for the mean and maximum dose. The rectum
and bladder were evaluated for the relative volumes that
received 70, 50 and 30 Gy (RBE) or Gy (V70, V50 and V30
respectively). The mean dose was obtained for the
rectum, bladder, left femoral head and right femoral
head.
In addition to the DVH analysis, normal tissue
complication probability (NTCP) was calculated for the
rectum and bladder. First, the DVHs of the RapidArc and
IMPT plans were exported from the Eclipse and XiO
TPSs, respectively, using the dose bin size of 50 cGy.





where TD50 is the tolerance dose for a 50% complication
rate at a specific time interval.15 The c50 is a unit less
model parameter that is specific to the normal structure
of interest and describes the slope of the dose–response
curve.15










where a is a unit-less model parameter that is specific to
the normal structure or tumour of interest, and vi is unit-
less and represents the ith partial volume receiving dose
Di in Gy.
15,16 Since the relative volume of the whole
Table 1. Dose–volume constraints for the planning target volume
(PTV), rectum, bladder and femoral heads.
PTV Maximum dose Minimum







Rectum <70 <65 <60
Bladder <75 <70 <65
Femoral
heads
Mean dose < 40 Gy
or Gy (RBE)
Dx%, dose received by x% of total OAR volume, where x% = 15, 25,
35 and 50. OAR, organ at risk; RBE, relative biological effectiveness.
Figure 1. Two 180° parallel-opposed lateral proton fields targeting the planning target volume (PTV) in IMPT plan for prostate cancer.
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structure of interest corresponds to 1, the sum of all
partial volumes vi will equal 1.
15,16 The EQD is the









where nf and df = D/nf are the number of fractions
and dose per fraction size of the treatment course
respectively. The a/b is the tissue-specific linear-quadratic
parameter of the organ being exposed.15,16 The EUD
calculations in this study were based on the parameters
listed in Table 2.
Two-sided Student’s t test was performed to calculate
the differences in the dosimetric and NTCP results
between the IMPT and VMAT plans, with P < 0.05 being
statistically significant.
Results
Table 3 provides averaged dosimetric and NTCP results,
whereas Figure 2 shows the dosimetric results of the
bladder and rectum of all 10 cases. The values inside the
parenthesis in this section are averaged over 10 analysed
cases.
The PTV maximum dose between IMPT and RapidArc
plans among all cases was found to be comparable
(P = 0.499). The PTV mean dose evaluation also showed
no significant difference (P = 0.088) between IMPT and
RapidArc plans. These PTV results suggest that the choice
of technique (IMPT or RapidArc) is less likely to make a
significant difference in the PTV doses.
However, the dosimetric impact of the treatment
technique was more distinct in the case of OARs,
especially in the low-dose (V30) and medium-dose (V50)
regions as shown in the Figure 1. For the bladder, the V30
and V50 were consistently lower in IMPT plans (23.2%
and 16.6% respectively) when compared to RapidArc
plans (50.9% and 25.1% respectively) with P < 0.000 for
V30 and P = 0.001 for V50. Similarly, the V30 and V50 of
the rectum were found to be lower in IMPT plans (21.0%
and 14.3% respectively) than in RapidArc plans (68.5%
and 45.0% respectively) with P < 0.000 for V30 and
P < 0.000 for V50. For the high-dose region (V70), IMPT
technique produced better rectal results compared to
RapidArc technique (6.9% vs. 12.8%; P < 0.000).
However, the V70 of the bladder was found to be
comparable in IMPT and RapidArc plans (9.7% vs.
10.5%; P = 0.111).
The mean doses of the rectum and bladder were found
to be significantly lower in IMPT plans (16.9 Gy (RBE)
and 17.5 Gy (RBE) respectively) when compared to
RapidArc plans (41.9 Gy and 32.5 Gy respectively) with
P < 0.000 for rectal mean dose and P < 0.000 for bladder
mean dose. However, RapidArc technique produced lower
mean dose for both the left femoral head (28.0 Gy (RBE)
vs. 18.0 Gy; P < 0.000) and right femoral head (27.4 Gy
(RBE) vs. 19.5 Gy; P < 0.000).
The NTCP results of the bladder and rectum for each
case are shown in Figure 3. For the bladder, there was no
Table 2. Parameters used to calculate normal tissue complication












Rectum Normal 1.8 44 5 2.7 80 2 8
Bladder Normal 1.8 44 7 3.6 80 2 3
100% dpf, 100% dose per fraction; #f, number of fractions; a, unit-
less model parameter that is specific to the normal structure; c50,
unit-less model parameter of normal tissue and describes the slope of
the dose–response curve; TD50, tolerance dose for a 50%
complication rate at a specific time interval; dpf, parameters’ source
data’s dose per fraction; a/b, alpha–beta ratio.
Table 3. Comparison of the dosimetric and normal tissue
complication probability (NTCP) results in intensity modulated proton
therapy (IMPT) and RapidArc plans.




























V30 (%) 21.0  9.6 68.5  10.0 <0.000
V50 (%) 14.3  5.8 45.0  10.0 <0.000
V70 (%) 6.9  3.4 12.8  3.6 <0.000











V30 (%) 23.2  7.0 50.9  15.6 <0.000
V50 (%) 16.6  5.4 25.1  9.6 0.001
V70 (%) 9.7  3.5 10.5  4.2 0.111





















The values are averaged over 10 analysed cases. (Note: Both IMPT
and RapidArc plans were normalised for the same PTV coverage). Vx,
relative volume of the rectum receiving x Gy or Gy (RBE); PTV,
planning target volume; RBE, relative biological effectiveness.
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clear trend with IMPT technique producing smaller
NTCP values over RapidArc, and the results in IMPT
(0.6  0.2%) and RapidArc (0.5  0.2%) plans were
found to be comparable (P < 0.152). However, for the
rectum, IMPT consistently produced lower NTCP among
all 10 cases with average values of 0.8  0.7% and
1.7  0.7% in IMPT and RapidArc plans respectively
(P < 0.000).
Discussion
The data presented in the current study show that IMPT
technique is capable of producing better dosimetric
results of rectal and bladder for the same PTV coverage
when compared to RapidArc technique. Similar findings
were reported by Vees et al.2 and Georg et al.3 The
reduction in bladder and rectal volumes exposed to
irradiation is very essential in order to minimise the
rectal and bladder toxicities. A paper by Michalski et al.13
showed that small rectal volumes receiving a high dose
were the most critical predictors of late toxicity.
Interestingly, two different studies11,12 correlated the late
rectal bleeding to the medium-dose (V50). The V70 and
V50 values for the rectum in the current study revealed
that IMPT could potentially reduce the late rectal
toxicities compared to RapidArc technique if V70 and V50
are considered to be the late toxicity predictors for the
rectum. Previous study5 on the prostate cancer cases
reported that RapidArc produced lower rectal V70 in two
cases when compared to USPT. However, the current
study shows that IMPT produced lower rectal V70 for all
cases as IMPT planning allows plan optimisation, which
is not available in USPT planning. Furthermore, lower
NTCP of the rectum in IMPT plans shows the potential
of reducing rectal toxicities compared to RapidArc plans.
A higher mean femoral head dose in IMPT plans is
mainly due to two parallel-opposed lateral fields used in
the planning, which passed through the left and right
femoral heads. However, the V40 of the left and right
femoral heads was found to be 0% for both IMPT and
Figure 2. Comparison of the dosimetric results of the bladder (top row) and rectum (bottom row) in intensity modulated proton therapy and
RapidArc plans of 10 high-risk prostate cancer cases. Vx = relative volume of the structure receiving x Gy or Gy(relative biological effectiveness
(RBE)).
Figure 3. The normal tissue complication probability of rectum and bladder in intensity modulated proton therapy and RapidArc plans of 10
prostate cancer cases.
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RapidArc plans, and this satisfied the dosimetric
constraint (V50 < 5%) of the femoral head.
17 For the
bladder, both IMPT and RapidArc techniques clearly met
the QUANTEC18 recommendation (i.e. no more than
35% of the bladder volume receive a dose greater than
70 Gy). The correlation between the toxicities of the
bladder and its dosimetric parameter, however, is yet to
be established.19 On average, smaller volumes of the
bladder were found to be exposed to irradiation using
IMPT than using RapidArc; however, the NTCPs of
bladder suggest that both the techniques are capable of
producing NTCP below 1% for the high-risk prostate
cases with seminal vesicles.
A number of assumptions were made in our study.
Treatment delivery schema was assumed to be 2 fields/
day and 2 arcs/day in IMPT and RapidArc planning
respectively. Single field per day delivery schema can also
be used for the prostate cancer treatment planning. Both
the double- and single-field techniques were found to
produce comparable dosimetric results in the proton20
and RapidArc planning.21 A nominal CT data set of each
case was used for proton and photon dose calculations
although it is possible to have a change in patient
anatomy during the course of treatment.
The PTV margin (3 mm to the posterior and 4 mm
elsewhere to the CTV) in the current study was based on
the institutional protocol for the prostate cancer with
seminal vesicles. More recent publication by Park et al.22
has suggested using a beam-specific PTV margin for the
proton plans which were generated based on single-field
optimisation technique. The beam-specific PTV margin in
proton therapy could account for setup and range
uncertainties. However, for the multi-field optimisation
(e.g. IMPT planning), the application of the beam-specific
PTV margin is not straightforward in our current version
of XiO TPS. Since our study was more focused on the
comparison between two different modalities, it made
more sense to use the geometry-based PTV for IMPT and
RapidArc planning.
In the current study, proton planning was done using
two parallel-opposed lateral beams. Some of the recent
publications have shown the feasibility of using non-
parallel-opposed proton beams in the treatment of prostate
cancer. For example, Trofimov et al.9 and Tang et al.23
reported that the anterior-oblique proton beams could
reduce the rectal dose when compared to two parallel-
opposed lateral fields. Rana et al.24 used anterior-oblique
beams for treatment planning of the prostate cancer cases
with a unilateral metallic hip prosthesis and reported more
favourable rectum and bladder results in IMPT plans than
in USPT plans. A clinical study by Cuaron et al.25 reported
acceptable low toxicities in the prostate cancer patients
treated with anterior-oblique beams in USPT.
IMPT plans are typically evaluated in terms of their
robustness, and dosimetric effect of translational and
rotational alignment errors are analysed. Recently, Pugh
et al.26 performed a robust analysis for the prostate cancer
plans generated by IMPT technique. It was reported that
rotational errors of up to 5° and translational errors of up
to 5 mm resulted in robust prescription dose coverage of
the CTV.26 Translational alignment errors could produce
larger dose perturbations to the rectum and bladder.26
Previous studies and the IMPT results from the current
study demonstrate the use of proton beams for the prostate
cancer treatment very promising; however, further study
investigating the radiobiological consequences due to
treatment setup variations (rotational and translational
errors) is warranted.
Conclusion
Both IMPT and RapidArc techniques provided comparable
mean and maximum PTV doses. For the rectum, IMPT
produced better dosimetric results in the low-, medium-
and high-dose regions and lower NTCP compared to
RapidArc. For the bladder, the NTCP and dosimetric
results in the high-dose region were comparable in both
sets of plans, whereas IMPT produced better dosimetric
results in the low- and medium-dose regions.
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